Smith Hunter C

CFO Smith Hunter C sold 7,954 shares at blended $101.31 on 2026-02-17 & 2026-02-19 for $805,813.77.

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 9 separate sales totaling 7,954 shares for $805,813.77 across two trading days (2026-02-17 and 2026-02-19), reducing his holdings from 118,466 to 110,512 shares (-6.7%). The transactions occurred at prices ranging from $99.42 to $103.84, near current levels ($103.16), with the blended average at $101.31. The company is currently unprofitable (net income $-52.9M in the latest full fiscal year) despite strong revenue growth of +68.1%, and the stock is -12.3% from its 52-week high of $117.62. His cross-ticker track record shows 20 prior sells with an average 90-day return of +26.3%, indicating his prior sells were generally followed by stock appreciation—a poorly-timed pattern. The multiple transactions and absence of FLAG annotations suggest these were discretionary sales rather than part of a structured 10b5-1 plan.

CFO Smith Hunter C sold 7,071 shares across 10 transactions (Feb 10-12) at avg $100.21; stock now $96.06.

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 10 separate sales totaling 7,071 shares for $708,575.59 across three trading days (Feb 10-12, 2026), with a blended average price of $100.21. Post-transaction holdings stand at 118,466 shares, a 5.6% reduction. The sales occurred as the stock has declined 10.9% over 30 days and 18.3% from its 52-week high of $117.62, now trading at $96.06—below the blended transaction price. His cross-ticker track record shows prior sells with an average 90-day return of +25.6%, though at this specific ticker (RYTM), measurable outcomes are limited, with only 1 prior sale showing a 90-day outcome (+4.0% return). The company remains unprofitable (net income $-52.9M in the latest full year) despite strong revenue growth of 68.1%, adding context to insider liquidity activity at a unprofitable, growth-stage biotech.

CFO Smith Hunter C sells 6,628 shares at $106.03 avg for $702.7K; current price $103.61 is -11.9% from 52-week high

Smith Hunter C, CFO of Rhythm Pharmaceuticals, executed 4 separate sales totaling 6,628 shares for $702,744.15 on 2026-02-04 and 2026-02-05, reducing holdings by 5.0% to 125,537 shares. The sales occurred at an average price of $106.03, which is 2.3% above the current price of $103.61 and within the 52-week trading range. Across his 5 prior sales at RYTM, the insider's timing track record shows 0 of 5 sales were well-timed at the 90-day mark (mean 90-day return +11.4%), indicating the insider has not consistently sold before downturns at this ticker. The company is currently unprofitable (net income $-52.9M) but growing revenue at +68.1% annually, creating a risk/reward context typical of high-growth biotech.

CFO Smith Hunter C sold 28,088 shares for $2,704,623.77 near 52-week high; stock up 61.0% in 90 days

Smith Hunter C (Chief Financial Officer) sold 24,611 shares at $96.33 on 2025-08-12 and 3,477 shares at $96.00 on 2025-08-13, totaling 28,088 shares for $2,704,623.77 at a blended average price of $96.29. The sales occurred near the stock's 52-week high of $97.86 (−1.4% from peak), following a 90-day rally of +61.0% and 30-day gain of +8.0%. The CFO reduced his holdings by 19.4%, from 145,003 shares to 116,915 shares post-transaction. Underlying company fundamentals show significant disparities: the latest quarter generated $48,502,000.00 in revenue with a net loss of −$46,632,000.00, though annual revenue growth reached +68.1% year-over-year. His prior five sales at RYTM all occurred within the last three months (July and May 2025), and his cross-ticker track record across eight prior open-market sales shows a 0.00% well-timed rate at the 90-day mark (average 90d return +9.4%), indicating that past sales have not preceded price declines. The timing context—sales near an all-time high after a sustained rally—contrasts sharply with the company's ongoing unprofitability, warranting attention to whether this represents a deliberate capital reallocation or a discrete portfolio adjustment.

CFO Smith Hunter C sold 42,120 shares at $80.48 blended avg on 2025-07-09, reducing stake by 26.5% to 116.9K shares

Chief Financial Officer Smith Hunter C executed three separate sales totaling 42,120 shares for $3,389,756.12 at prices ranging from $75.38 to $84.50, reducing his post-transaction holdings from 159,035 to 116,915 shares. The company is unprofitable (net income $-49,498,000.00 in the most recent full fiscal year) despite strong revenue growth of 68.1% year-over-year, creating a tension between execution momentum and financial fundamentals that warrants investor attention. Notably, at this ticker the insider's prior sales have shown poor timing: 0 of 3 prior sells (as of the last 90-day measurable outcomes) saw the stock decline afterwards—all posted positive returns post-sale. The current stock price of $86.70 has risen 45.6% over 90 days and 33.7% over 30 days from prior low points, raising questions about whether this large single-day liquidation signals revaluation concerns or reflects calendar scheduling.

CFO Smith Hunter C sells 23,400 shares (17.6% of holdings) at $61.41 blended average; stock at $65.67 (2.5% from 52-week high)

CFO Smith Hunter C executed 2 separate sales totaling 23,400 shares for $1,437,010.37 on 2025-05-30 at a blended average price of $61.41, reducing his holdings from 133.3K to 109.9K shares. At current price of $65.67, the stock has appreciated 2.6% over 30 days and 24.0% over 90 days, trading 2.5% below its 52-week high of $67.33. Across his cross-ticker track record (3 prior sells), this insider's sales have averaged a 90-day return of +9.4% with 0.00% well-timed rate, indicating prior sales were followed by gains. At RYTM specifically, the insider's prior 3 sales (2024-03-19, 2023-12-06, 2023-12-05) all showed positive 90-day returns (ranging from +3.1% to +20.1%), with 0 of 3 well-timed at the 90-day mark—a pattern suggesting recent-window positioning rather than downside conviction. The company remains unprofitable ($-49.5M net income on $32.7M quarterly revenue) despite strong 68.1% annual revenue growth, creating structural uncertainty that may explain insider liquidity activity at elevated valuations.